168 373

Cited 0 times in

A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.

Woo, HY; Bae, SH; Park, JY; Han, KH; Chun, HJ; Choi, BG; Im, HU; Choi, JY; Yoon, SK; Cheong, JY; Cho, SW; Jang, BK; Hwang, JS; Kim, SG; Kim, YS; Seo, YS; Yim, HJ; Um, SH
Cancer chemotherapy and pharmacology, 65(2):373-382, 2010
Journal Title
Cancer chemotherapy and pharmacology
PURPOSE: Hepatic arterial infusion chemotherapy (HAIC) has been reported to be effective in patients with advanced hepatocellular carcinoma (HCC).

METHODS: In this multicenter, prospective, open-labeled, clinical trial, we randomly assigned 68 patients with advanced HCC to receive either low-dose [n = 32, 5-fluorouracil (FU), 170 mg/m(2) and cisplatin, 7 mg/m(2) on days 1-5] or high-dose HAIC (n = 36, 5-FU, 500 mg/m(2) on days 1-3 and cisplatin, 60 mg/m(2) on day 2) every 4 weeks via an implantable port system.

RESULTS: A total of 207 cycles of HAIC was given to the 68 patients. Overall, 6 patients (8.8%) achieved a partial response and 21 patients (30.9%) had stable disease. The objective response rate (CR + PR) was significantly improved in the high-dose group compared to the low-dose group (16.7% vs. 0%, P = 0.024). The median time to disease progression and overall survival were slightly prolonged in the high-dose group compared to the low-dose group (median survival, 193 vs. 153 days; P = 0.108; median time to disease progression, 145 vs. 90 days; P = 0.095). Multivariate analysis showed that tumor response to treatment [P = 0.007, RR 2.27 (95% CI, 1.248-4.132)] was the only factor associated with overall survival. All adverse events were tolerable and successfully managed in both treatment groups.

CONCLUSIONS: Both HAIC regimens are safe and effective in patients with advanced HCC. High-dose HAIC achieves a better tumor response compared to low-dose HAIC.
MeSH terms
AdultAgedAntineoplastic Combined Chemotherapy Protocols/administration & dosage/adverseCarcinoma, Hepatocellular/*drug therapy/mortality/pathologyCisplatin/administration & dosageDrug Administration ScheduleFemaleFluorouracil/administration & dosageHepatic ArteryHumansInfusions, Intra-ArterialLiver Neoplasms/*drug therapy/mortality/pathologyMaleMiddle AgedPrognosisProspective StudiesSurvival Rate
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
AJOU Authors
정, 재연조, 성원
Files in This Item:
Full-Text Not Available.txtDownload
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.